Appointment dossier — Endometrial Carcinoma

Compounds studied in Endometrial Carcinoma

• Durvalumab — Human evidence · 0 positive / 1 negative-mixed · PMID 36512912
• Sacituzumab Govitecan — Animal evidence · 1 positive · PMID 40344963

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT07319429 · Phase 2 / Phase 3 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (China)
• NCT07198074 · Phase 3 — Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (United States)
• NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
• NCT04851119 · Phase 1 / Phase 2 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (United States)
• NCT06518564 · Phase 2 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer (United States)
• NCT07070518 · Phase 1 / Phase 2 — Study of GV20-0251 in Participants With Solid Tumor Malignancies (China)
• NCT05542407 · Phase 1 — ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (United States)
• NCT06365905 — Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding (United States)
• NCT06348719 — Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer. (France)
• NCT05647109 — Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer (China)
• NCT07407959 — Screening and Staging of Benign vs Malignant Pelvic Abnormalities (United States)
• NCT07062016 — Molecular and ctDNA Characterization of High-Risk Endometrial Cancer (United States)
• NCT06851663 · Phase 2 / Phase 3 — Trop2-targeted immunoPET Imaging of Solid Tumors (China)
• NCT07262619 · Phase 1 / Phase 2 — EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (United States)
• NCT04300556 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (United States)
• NCT05797168 · Phase 1 / Phase 2 — Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors (United States)
• NCT04104776 · Phase 1 / Phase 2 — A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (United States)
• NCT06760819 · Phase 2 — A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (United States)

Most-relevant first: trials that name Endometrial Carcinoma, then broader trials you may still qualify for. 335 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Durvalumab has been studied in people for Endometrial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
2. Of the open trials I found (for example NCT07319429), am I eligible for any — here or at a larger cancer center?
3. What is my exact diagnosis — the type, subtype, stage, and grade?
4. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
5. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
6. What is the goal of treatment for me — cure, long-term control, or comfort?
7. What are all of my standard treatment options, and what does each one involve?
8. What is the realistic benefit of each option, in actual numbers?
9. What are the most common and the most serious side effects, and how are they managed?
10. How will we know if treatment is working, and how often will I be scanned or tested?
11. If the first treatment doesn't work, what are the next options?
12. Are there gentler options if I want to prioritize quality of life?
13. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
14. Is my case reviewed by a multidisciplinary tumor board?
15. Would a second opinion at a center that treats my cancer often be worthwhile?
16. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
17. Which symptoms are emergencies, and who do I call after hours?
18. Should I see palliative or supportive care alongside my treatment?
19. How will treatment affect my daily life, work, and (if it matters to me) fertility?
20. What can I safely do myself — diet and activity — and is anything I'm taking risky?
21. What will treatment cost, and is financial assistance available?
22. Should my tumor tissue be stored (biobanked) for future testing or trials?